Elutia
ELUT

$4.14

3.72%

Market Cap: $141M

About: Elutia Inc Formerly Aziyo Biologics Inc is a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing surgery, concentrating on patients receiving implantable medical devices. The company's segments include Device Protection, Women's Health and Cardiovascular. It generates maximum revenue from the Women's Health segment. The products of the company are targeted to address unmet clinical needs with the goal of promoting healthy tissue formation and avoiding complications associated with medical device implants, such as scar-tissue formation, capsular contraction, erosion, migration, non-union of implants and implant rejection.

Employees: 54

Healthcare Biological Products, Except Diagnostic Substances

0

Funds holding %

of 6,710 funds

0

Analysts bullish %

of 5 analysts

Fund manager confidence

Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)

400% more first-time investments, than exits

New positions opened: 5 | Existing positions closed: 1

200% more funds holding in top 10

Funds holding in top 10: 1 [Q1] → 3 (+2) [Q2]

198% more capital invested

Capital invested by funds: $17.9M [Q1] → $53.4M (+$35.5M) [Q2]

100% more repeat investments, than reductions

Existing positions increased: 10 | Existing positions reduced: 5

18% more funds holding

Funds holding: 22 [Q1] → 26 (+4) [Q2]

17.9% more ownership

Funds ownership: 28.51% [Q1] → 46.4% (+17.9%) [Q2]

See Fund Rankings

Research analyst outlook

5 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$10

142%

upside

Avg. target

$10.40

151%

upside

High target

$11

166%

upside

5 analyst ratings

5 positive

100%

0 neutral

0%

0 negative

0%

Cantor Fitzgerald Ross Osborn 37% 1-year accuracy 22 / 60 met price target	142%upside $10	Overweight Reiterated	6 Sept 2024
Cantor Fitzgerald Ross Osborn 37% 1-year accuracy 22 / 60 met price target	142%upside $10	Overweight Maintained	8 Aug 2024
Lake Street Frank Takkinen 42% 1-year accuracy 8 / 19 met price target	142%upside $10	Buy Maintained	21 Jun 2024
Cantor Fitzgerald Ross Osborn 37% 1-year accuracy 22 / 60 met price target	166%upside $11	Overweight Maintained	20 Jun 2024
Cantor Fitzgerald Ross Osborn 37% 1-year accuracy 22 / 60 met price target	166%upside $11	Overweight Maintained	18 Jun 2024

See Analyst Rankings

Financial journalist opinion

Based on 4 articles about ELUT published over the past 30 days

Elutia Celebrates First Year

Company Thanks Stakeholders and Employees for a Year of Remarkable Growth and Accomplishment SILVER SPRING, Md., Sept. 06, 2024 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia”), a pioneer in drug-eluting biomatrix products, is celebrating its one-year anniversary and the team that made it possible.

Elutia Celebrates First Year

Elutia Announces First Patient Implant of EluPro™, the World's First Drug-Eluting BioEnvelope for Cardiac Pacemakers and Neurostimulators

SILVER SPRING, Md., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia”), a pioneer in drug-eluting biomatrix products, today announced a landmark achievement with the first-ever patient implant of EluPro®, the world's first antibiotic-eluting biologic envelope cleared by the U.S. Food and Drug Administration (FDA). The groundbreaking procedure was performed by John Catanzaro, MD, MBA, Chief, Division of Cardiology, Director, Cardiology Services, and Program Director of Clinical Cardiac Electrophysiology Fellowship at East Carolina University Health Medical Center in Greenville, North Carolina.

Elutia Announces First Patient Implant of EluPro™, the World's First Drug-Eluting BioEnvelope for Cardiac Pacemakers and Neurostimulators

Elutia to Participate in Upcoming Investor Conferences

SILVER SPRING, Md., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia”), a pioneer in drug-eluting biomatrix products, today announced that Dr. Randy Mills, President and Chief Executive Officer, and Matt Ferguson, Chief Financial Officer, will participate in the following upcoming investor conferences in New York:

Elutia to Participate in Upcoming Investor Conferences

Presenting on the Emerging Growth Conference 74 Day 1 on August 21 Register Now

MIAMI, Aug. 20, 2024 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 74th Emerging Growth Conference on August 21 – 22, 2024.

Presenting on the Emerging Growth Conference 74 Day 1 on August 21 Register Now

Elutia Inc. (ELUT) Q2 2024 Earnings Call Transcript

Elutia Inc. (NASDAQ:ELUT ) Q2 2024 Earnings Conference Call August 7, 2024 4:30 PM ET Company Participants Matt Steinberg - Finn Partners, IR Randy Mills - President and CEO Matt Ferguson - Chief Financial Officer Conference Call Participants Matthew Park - Cantor Fitzgerald Frank Takkinen - Lake Street Capital Markets Operator Greetings. Welcome to the Elutia Second Quarter 2024 Financial Results Call.

Elutia Inc. (ELUT) Q2 2024 Earnings Call Transcript

Elutia Appoints Ryan Marques, Ph.D., MBA as Vice President of Operations

SILVER SPRING, Md., July 31, 2024 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia”), a pioneer in drug-eluting biomatrix products, today announced the appointment of Ryan Marques, Ph.D, MBA as Vice President of Operations. Dr. Marques brings more than 20 years of experience leading operations teams across manufacturing, quality assurance, supply chain and technical services in the device and pharmaceutical industries.

Elutia Appoints Ryan Marques, Ph.D., MBA as Vice President of Operations

Elutia to Present at the Emerging Growth Conference on Thursday, July 18

SILVER SPRING, Md., July 11, 2024 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia”), a pioneer in drug-eluting biomatrix products, today announced that Dr. Randy Mills, President and Chief Executive Officer, will present at the Emerging Growth Conference on Thursday, July 18, 2024, at 12:35 p.m. ET (9:35 a.m. PT).

Elutia to Present at the Emerging Growth Conference on Thursday, July 18

7 Growth Stocks to Buy for Under $5 for Massive Gains

With growth stocks under $5, the focal point is rather obvious: putting woodwork on the ball as aggressively as possible. Of course, swinging for the fences comes with significant risks.

7 Growth Stocks to Buy for Under $5 for Massive Gains

Zacks Investment Research

3 Best Breakout Stocks Worth a Buy for Attractive Returns

BRC (BRCC), Costamare (CMRE) and Elutia (ELUT) have been selected as the breakout stocks for today.

3 Best Breakout Stocks Worth a Buy for Attractive Returns

Elutia Announces $13.26 Million Registered Direct Offering

SILVER SPRING, Md., June 17, 2024 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”) today announced it has entered into a definitive agreement with investors for the purchase and sale of 3,175,000 shares of the Company's Class A common stock at a purchase price of $3.40 per share and 725,000 prefunded warrants to purchase up to 725,000 shares of the Company's Class A common stock at a purchase price of $3.399 per prefunded warrant in a registered direct offering. The prefunded warrants are immediately exercisable at an exercise price of $0.001 per each prefunded warrant. The gross proceeds to Elutia from the offering are expected to be approximately $13.26 million, before deducting placement agent fees and other offering expenses payable by Elutia. The offering is expected to close on or about June 18, 2024, subject to customary closing conditions.

Elutia Announces $13.26 Million Registered Direct Offering

See News Rankings